JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boldt, J.
Right arrow Articles by Isgro, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boldt, J.
Right arrow Articles by Isgro, F.
Related Collections
Right arrow Surgery
Right arrow Heart
Right arrow Pharmacology

Anesth Analg 2004;99:1009-1017
© 2004 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000132969.88550.96

CARDIOVASCULAR ANESTHESIA

The Prophylactic Use of the ß-Blocker Esmolol in Combination with Phosphodiesterase III Inhibitor Enoximone in Elderly Cardiac Surgery Patients

Joachim Boldt, MD PhD*, Christian Brosch, MD*, Andreas Lehmann, MD*, Stephan Suttner, MD*, and Frank Isgro, MD{dagger}

Departments of *Anesthesiology and Intensive Care Medicine and {dagger}Cardiac Surgery, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany

Address correspondence and reprint requests to Prof. Dr. Joachim Boldt, Department of Anesthesiology and Intensive Care Medicine, Klinikum der Stadt Ludwigshafen, Bremserstr. 79, Ludwigshafen, Germany. Address e-mail to boldtj{at}gmx.net


   Abstract
Top
 Abstract
Introduction
 Methods
 Results
 Discussion
 References
 
We assessed the influence of the prophylactic use of a combination of the IV ß-adrenergic blocker, esmolol, and the phosphodiesterase III inhibitor, enoximone, on postbypass hemodynamic status, inflammation, and endothelial and organ function in a prospective, randomized, placebo-controlled study in 42 patients aged >65 yr undergoing aortocoronary bypass grafting. In 21 patients, esmolol (aim: heart rate <70 bpm) plus enoximone (initial bolus of 0.5 mg/kg followed by a continuous infusion of 2.5 µg · kg–1 · min–1) was started after induction of anesthesia and continued until the morning of the first postoperative day; another 21 patients received saline solution as placebo. Hemodynamics, splanchnic perfusion (gastric-arterial CO2 gap), liver function (glutathione transferase-{alpha} plasma levels), renal function (creatinine clearance, urine concentrations of N-acetyl-ß-D-glucosaminidase), myocardial ischemia (creatine-kinase MB and troponin T plasma levels), inflammation (elastase, interleukin-6 and -8 plasma levels), and endothelial integrity (adhesion molecules plasma levels) were assessed at baseline, before and after cardiopulmonary bypass (CPB), and in the intensive care unit until the first postoperative day. Catecholamine requirements were significantly less in the treated than in the nontreated patients. Heart rate was significantly slower, cardiac index was higher, and gastric-arterial CO2 gap was significantly lower in the treatment group. Troponin T, ß-N-acetyl-ß-D-glucosaminidase, glutathione transferase-{alpha}, and soluble adhesion molecules increased significantly in the untreated control, but remained almost normal in the esmolol+enoximone patients. Inflammatory responses (elastase/interleukins) were attenuated by esmolol+enoximone. We conclude that, in comparison to an untreated control, the prophylactic use of a combination of esmolol and enoximone in elderly patients undergoing cardiac surgery with cardiopulmonary bypass resulted in overall beneficial effects on postbypass hemodynamic status, organ function, inflammatory response, and endothelial integrity.

IMPLICATIONS: Compared with an untreated control group, the prophylactic use of an IV combination of the ß-adrenergic blocker, esmolol, and the phosphodiesterase III inhibitor, enoximone, in elderly patients undergoing cardiac surgery with cardiopulmonary bypass resulted in beneficial effects on postbypass hemodynamic status, splanchnic perfusion, organ function, as well as inflammatory response and endothelial integrity.


   Introduction
Top
 Abstract
 Introduction
Methods
 Results
 Discussion
 References
 
Cardiac surgery has been expanded to increasingly elderly patients. Improvements in surgical techniques, cardiopulmonary bypass (CPB) equipment, and anesthesia management have been associated with improved outcome, even in those patients who were not candidates for cardiac surgery in the past. However, myocardial infarction, postoperative low output syndrome, or postbypass organ failure are still alarming complications in cardiac surgery. One reason for postoperative low output syndrome is the failing heart secondary to ischemic damage. Additionally, CPB is associated with complex pathophysiological processes that have been compared with the alterations seen in sepsis or systemic inflammatory response syndrome. The bypass-related inflammatory response combined with alterations in macro- and microcirculatory blood flow may result in development of (multi-) organ damage and subsequently may be associated with negative outcome.

The complexity of the pathogenesis of postbypass organ failure may offer many opportunities for pharmacological interventions. Prevention of perioperative myocardial ischemia represents an important approach to improve postoperative outcome. At present, use of ß-adrenergic blockers seems to be the most effective regimen to reduce cardiac morbidity and mortality (1–4). Use of ß-receptor stimulating substances (e.g., epinephrine) is often needed in cardiac surgery patients to treat myocardial pump failure and subsequently prevent low output syndrome. Because catecholamines show reduced efficacy in ß-blocked patients, use of phosphodiesterase (PDE) III inhibitors is an interesting alternative to catecholamines in this situation (5). Secondary to their vasodilatory properties, these drugs may also improve organ perfusion and microcirculatory blood flow (6–8).

Increased cyclic nucleotides adenosine monophosphate, guanosine monophosphate related to PDE III inhibition or ß-adrenergic stimulation may be associated with increased incidence of dysrhythmias, especially in ischemic tissues or during reperfusion (9). ß-Adrenergic blockers have been shown to be of benefit in protecting patients from sudden death, but do have considerable negative inotropic effects. This may limit their use in patients who are at risk to develop low output failure. Thus, it seems reasonable that a combination of both approaches (PDE III-induced positive inotropy and ß-receptor blockade) might offer advantages by producing beneficial effects and by compensating each other’s limitations in a complementary manner (10,11). The present study was designed to assess whether the prophylactic use of a combination of the IV ß-adrenergic blocker esmolol with the PDE III inhibitor enoximone before CPB possesses protective properties in elderly patients undergoing cardiac surgery.


   Methods
Top
 Abstract
 Introduction
 Methods
Results
 Discussion
 References
 
After approval of the local human ethics committee and informed consent, 42 patients aged >65 yr scheduled for first-time elective aortocoronary bypass grafting were included in the study. Severely reduced myocardial function (left ventricular ejection fraction <30%), myocardial infarction <1 mo before surgery, New York Heart Association class IV, liver insufficiency (aspartate aminotransferase >40 U/L, alanine aminotransferase >40 U/L), renal insufficiency (serum creatinine >2.0 mmol/L), diabetes mellitus requiring insulin, or treatment with corticosteroids or cyclooxygenase inhibitors before surgery were defined as exclusion criteria.

When heart rate (HR) was >70 bpm before anesthesia, the patients were randomly assigned to 2 groups: 21 patients received a combination of IV ß-adrenergic blocker esmolol (aim: HR <70 bpm; Baxter, Unterschleissheim, Germany) plus the PDE III inhibitor enoximone (initial bolus of 0.5 mg/kg followed by a continuous infusion of 2.5 µg · kg–1 · min–1; Myogen, Bonn, Germany) (esmolol+enoximone group). Infusions were started after induction of anesthesia (after baseline measurements had been obtained) and were continued until the morning of the first postoperative day (POD). Another 21 patients received saline solution as placebo (control group).

Weight-related doses of sufentanil, midazolam, and pancuronium bromide were used to induce and maintain anesthesia. Controlled mechanical ventilation was used in all patients. Ventilation patterns were adjusted to keep arterial oxygen saturation >95% (measured by continuous pulse oximetry) and CO2 between 35 and 40 mm Hg (measured by continuous capnometry).

CPB was performed using a nonpulsatile pump and a membrane oxygenator (Optima XPTM; Stöckert Instrumente, Munich, Germany). The (nonheparinized) circuit was primed with 1000 mL of Ringer’s solution plus 500 mL of gelatin. Standard large-dose aprotinin regimen was used in all patients (2 million units as an initial loading dose followed by a continuous infusion of 500,000 U/h). Temperature was kept at almost normothermia (target bladder temperature: 33°–35°C). A flow rate of 2.4 L/min · m2 was maintained continuously. If necessary, norepinephrine was given to keep perfusion pressure during CPB between 50 and 60 mm Hg. Ringer’s solution was added to the circuit to maintain filling volume. When hemoglobin was <7 g/dL, packed red blood cells were administered. As much pump blood as necessary to keep pulmonary capillary wedge pressure (PCWP) between 12 to 15 mm Hg was infused during weaning off bypass. After CPB, the residual blood remaining in the extracorporeal circuit was concentrated using a cell salvage device and the autologous blood was retransfused until the end of the operation. Shed mediastinal blood was not retransfused in the postoperative period.

After surgery, all patients were transferred to the intensive care unit (ICU). Controlled mechanical ventilation was continued for at least 4 h. Tracheal extubation was performed when hemodynamics were stable for 1/2 h, temperature was >36°C, and the patient breathed spontaneously with adequate blood gas analyses. PCWP was kept between 12–15 mm Hg by administrating gelatin. Dobutamine was administered when mean arterial blood pressure (MAP) was <60 mm Hg, cardiac index (CI) was <2.0 L · min–1 · m2, and systemic vascular resistance (SVR) was >1200 dyne · s · cm–5. Target for CI was 2.0–3.0 L · min–1 · m–2. Epinephrine was administered when MAP was <60 mm Hg, CI was <2.0 L · min–1 · m2, and SVR was <1000 dyne · s · cm–5 despite sufficient volume infusion (PCWP 12–15 mm Hg). Target for CI was 2.0–3.0 L · min–1 · m–2. Norepinephrine was administered when SVR was <600 dyne · s · cm–5 and MAP was <60 mm Hg (target for SVR: 600–1000 dyne · s · cm–5). No steroids or nonsteroidal antiinflammatory drugs were given throughout the investigation period.

Patients’ entire perioperative management was performed by anesthesiologists and intensivists who were not involved in the study and blinded to the grouping.

Intra- and postoperative hemodynamic monitoring included continual measurement of HR, MAP, pulmonary artery pressure, PCWP, central venous pressure, and cardiac output (CO, thermodilution technique using a pulmonary artery catheter); derived hemodynamic variables (SVR, CI) were calculated from standard formulas.

Splanchnic perfusion was assessed by monitoring gastric mucosal partial pressure of carbon dioxide (PrCO2) using continuous gas tonometry (TonocapTM; Datex, Helsinki, Finland) and a gastric tonometric TRIP-catheter (Tonometrics; Datex). Difference of gastric PCO2 and arterial PaCO2 difference was calculated (CO2 gap).

Myocardial ischemia was assessed by measuring troponin T plasma levels (normal values: <0.1 ng/mL) and creatine-kinase MB mass (CK-MB; normal <6% from total CK plasma levels) using routine laboratory techniques.

Renal function was assessed by measuring serum and urine creatinine concentrations (Jaffé reaction) and creatinine clearance were calculated (Ucrea x Uvol/Pcrea x duration of urine collection period [Ucrea = urine creatinine concentration, Uvol = urine volume during the collection period, Pcrea = serum creatinine concentration]). Urine concentrations of N-acetyl-ß-D-glucosaminidase (ß-NAG; measured by a spectrophotometric method [Hoffmann La-Roche, Basel, Switzerland; normal values in healthy volunteers: <7 U/L]) were measured to assess tubular integrity. ß-NAG is a sensitive marker of lysosomal tubular damage, it is derived from the proximal tubule, and indicates minor and reversible tubular lesions (12,13). Collection periods of urine were from baseline to end of surgery, from end of surgery to 5 h after surgery, and from 5 h after surgery to 8:00 AM on the first POD.

Glutathione transferase (GST)-{alpha} (quantitative enzyme immunoassay [Enzyme Immunoassay HepkitTM; Biotrin, Dublin, Ireland], reference range of GST-{alpha} is 0–7.5 µg/L) plasma levels were measured to assess liver function. GST-{alpha} has been reported to be more sensitive to evaluate hepatocellular damage than conventional markers for assessing liver function (14).

Endothelial function was assessed by measuring plasma levels of soluble (s) adhesion molecules from arterial blood samples (sE-selectin, normal values: <30 ng/mL; vascular cell adhesion molecule-1 [sVCAM-1], normal values: <550 ng/mL; intercellular adhesion molecules [sICAM-1], normal values: 60 ng/mL). Measurements were done with commercially available solid-phase enzyme-linked immunosorbent assay kits based on the sandwich principle (Diagnostic International, Schriesheim, Germany). All analyses were performed in duplicate according to the instructions of the manufacturer by a single operator who was blinded to the grouping of the patients.

To assess the degree of inflammation, plasma levels of polymorphonuclear (PMN)-elastase (Merck, Darmstadt, Germany) as well as interleukin (IL)-6 and IL-8 were measured in duplicate from arterial blood samples using commercially available solid-phase two-site chemiluminescent enzyme immunometric assays (Diagnostic Product Corporation, Los Angeles, CA). Normal values (measured in healthy volunteers) for PMN-elastase are 29–86 µg/L, for IL-6 <5 pg/mL, and for IL-8 <60 pg/mL.

Measurements were performed after induction of anesthesia before esmolol+enoximone administration was started (T0), immediately before start of CPB (T1; only hemodynamics), 30 min after start of CPB (T2, only hemodynamics), 15 min after CPB (T3; only hemodynamics), at the end of surgery (T4), 5 h after surgery in the ICU (T5), and on the morning of the first POD (T6).

A formal sample-size calculation was performed before start of the study. A previous investigation in cardiac surgery patients (15) was used to evaluate the necessary number of patients. A 50% reduction in the increase of soluble adhesion molecules after CPB by administration of the combination of esmolol and enoximone was considered of relevant importance. Using the standard deviation (SD) of sE-selectin, sVCAM-1, and sICAM-1, an {alpha} error of 0.05 (two-sided) and a type II error of 0.2, 20 patients per group were determined to be necessary.

All data were expressed as mean and SD unless otherwise indicated. An SPSS/PC+ software package was used for statistical analyses (version 4.0; SPSS, Inc., Chicago, IL). All categorical variables were tested by {chi}2 test. All normally distributed data (tested by Kolmogorov-Smirnov test) were analyzed using Student’s t-test. One- and two-way analysis of variance (ANOVA) with repeated measures and post hoc Scheffé test were used to determine the effects of group, time, and group-time interaction. Mann-Whitney U-test or the Kruskal-Wallis H test was also used when appropriate. A P value < 0.05 was considered significant.


   Results
Top
 Abstract
 Introduction
 Methods
 Results
Discussion
 References
 
The two groups did not differ significantly with regard to demographic data, preoperative medication, preoperative myocardial function, and outcome (Table 1). Control patients needed more catecholamines (dobutamine, epinephrine, and norepinephrine) than the treated patients (Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1. Demographic Data and Data from the Perioperative Period
 

HR was significantly more rapid in the control than in the treatment group. CI, DO2, and VO2 increased significantly only in the esmolol+enoximone-treated patients and were significantly higher than in the control group until the end of the study period (Table 2).


View this table:
[in this window]
[in a new window]
  		Table 2. Hemodynamics in the Two Groups
 

Markers of myocardial ischemia (troponin T, CK-MB) increased in both groups, but control patients showed significantly higher plasma levels after surgery and in the ICU than the esmolol+enoximone-treated patients (control: troponin T from 0.1 ± 0.1 to 0.9 ± 0.7 ng/L 5 h after surgery; treatment group: from 0.1 ± 0.1 to 0.4 ± 0.2 ng/L 5 h after surgery) (Fig. 1).


Figure 1
View larger version (18K):
[in this window]
[in a new window]
  		Figure 1. Changes of plasma levels of troponin T and creatine kinase (CK) and CK-MB mass; mean ± SD; +P < 0.05 different to baseline data, *P < 0.05 different to the other group. Beta+enox = esmolol+enoximone, ICU = intensive care unit, POD = postoperative day; the dashed line indicates normal range.

 
Creatinine clearance slightly decreased after CPB in the control patients, but remained within normal range in both groups. ß-NAG urine concentrations increased in the control (from 4.0 ± 0.1 to 18.1 ± 3.5 U/L) and remained almost unchanged in the treatment group (Fig. 2).


Figure 2
View larger version (18K):
[in this window]
[in a new window]
  		Figure 2. Changes of creatinine clearance (normal: 80–120 mL/min) and urine concentrations of N-acetyl-ß-D-glucosaminidase (beta-NAG; normal values: 0–7 U/L]); mean ± SD; +P < 0.05 different to baseline data, *P < 0.05 different to the other group. Beta+enox = esmolol+enoximone, ICU = intensive care unit, POD = postoperative day; the dashed line indicates normal range.

 
After CPB and in the subsequent postbypass period, PCO2 gap was significantly higher in the untreated control group than in the esmolol+enoximone patients (Fig. 3). GST-{alpha} plasma levels were within normal range at baseline in both groups (Fig. 3). They increased only in the control patients (from 4.8 ± 1.1 to 15.3 ± 3.0 U/L).


Figure 3
View larger version (17K):
[in this window]
[in a new window]
  		Figure 3. Changes of plasma levels {alpha}-glutathione S-transferase (GST-alpha; normal value: 0–7.5 µg/L) and the difference of gastric and arterial PCO2 (CO2 gap); mean ± SD; +P < 0.05 different to baseline data, *P < 0.05 different to the other group. Beta+enox = esmolol+enoximone, ICU = intensive care unit, POD = postoperative day; the dashed line indicates normal range.

 
At baseline, PMN-elastase, IL-6, and IL-8 plasma levels were within normal range in both groups. They increased significantly more after CPB in the control patients (e.g., IL-6: from 3.8 ± 0.4 to 352 ± 66 pg/mL 5 h after CPB versus from 4.2 ± 0.3 to 139 ± 26 pg/mL in the treated group). At the first POD, all markers of inflammation were more than at baseline in both groups, but the untreated control patients showed significantly higher plasma levels than the esmolol+enoximone patients (Fig. 4).


Figure 4
View larger version (20K):
[in this window]
[in a new window]
  		Figure 4. Changes of plasma levels of polymorphonuclear (PMN)-elastase, interleukin (IL)-6 (normal values: <5 pg/dL), and IL-8 (normal values: <60 pg/mL); mean ± SD; +P < 0.05 different to baseline data, *P < 0.05 different to the other group. Beta+enox = esmolol+enoximone, ICU = intensive care unit, POD = postoperative day; the dashed line indicates normal range.

 
Plasma levels of all measured soluble adhesion increased significantly after CPB only in the untreated control group (e.g., sE-selectin: from 22 ± 8 to 75 ± 8 ng/mL 5 h after CPB) and did not reach normal values at the first POD. In the treatment group, plasma levels of adhesion molecules remained almost unchanged and within normal range throughout the study period (Fig. 5).


Figure 5
View larger version (21K):
[in this window]
[in a new window]
  		Figure 5. Changes of soluble (s) E-selectin (sE-selectin; normal values: <30 ng/mL], soluble (s) intercellular adhesion molecules (sICAM-1; normal value: <60 ng/mL), and soluble (s) vascular cell adhesion molecule-1 (sVCAM-1; normal values: <600 ng/mL); mean ± SD; +P < 0.05 different to baseline data, *P < 0.05 different to the other group. Beta+enox = esmolol+enoximone, ICU = intensive care unit, POD = postoperative day; the dashed line indicates normal range.

 

   Discussion
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
References
 
The percentage of population aged >60 years will increase dramatically in the coming years. Because elderly patients have a narrower physiological reserve and often have coexisting diseases, they are at increased risk of perioperative morbidity and mortality. Perioperative mortality in the elderly undergoing coronary artery bypass surgery is 3–7 times more than younger cohorts (16–18). Thus, we have decided to include patients aged >65 years to assess the benefits of the prophylactic use of a combination of the IV ß-adrenergic blocker and PDE III inhibitor before CPB.

Hemodynamic and biochemical markers of myocardial dysfunction and of regional ischemia immediately after surgery and in the ICU portrayed adverse outcome in the elderly cardiac surgery patient. The major results of the present study were that prophylactic IV administration of the ß-adrenergic blocker esmolol and PDE III inhibitor enoximone in our elderly patients resulted in overall beneficial effects on hemodynamics, inflammation, endothelial integrity, and organ function in comparison to an untreated control group.

Our understanding of the inflammatory reactions to CPB has been improved in recent years, enabling the development of novel therapies focused on reducing the inflammatory response (19,20). Cytokines and adhesion molecules have a central role in the inflammatory response in this situation (21). For example, IL-8 attracts and activates PMN leukocytes, it is crucial in the formation of pulmonary and myocardial ischemic-reperfusion injury as well as in proximal tubular injury after CPB. Therefore, pharmacological manipulation of whole body inflammatory response has received some attention in the cardiac surgery patient (22). Many approaches have been tried to selectively block certain cytokines, but most of these specific regimens have failed. We used PDE III inhibitors because they not only provide beneficial hemodynamic effects, but an increase of intracellular cyclic adenosine monophosphate and/or cyclic guanosine monophosphate concentration by inhibition of PDE has also been shown to beneficially modulate inflammatory response (23). These antiinflammatory capabilities may offer another potential mechanism for clinical efficacy of PDE III inhibitors (5,7). In experimental studies, enoximone inhibited FMLP (methionyl-leucyl-phenylalanine)-stimulated neutrophil oxygen radical production indicating oxygen free radical scavenging (24). In septic shock patients, treatment with the PDE III inhibitor enoximone (2.5–10 µg · kg–1 · min–1) resulted in increased hepatosplanchnic VO2, increased indocaine metabolism, and decreased release of hepatic tumor necrosis factor-{alpha} indicating improved hepatosplanchnic function and antiinflammatory properties (25). Administration of enoximone (5 µg · kg–1 · min–1) started before CPB and continued for the following 24 hours diminished endotoxin levels in liver venous blood indicating beneficial effects on tissue damage and barrier function of the gut (26).

PDE III inhibitors, however, may increase myocardial oxygen consumption and may have (fatal) dysrhythmogenic effects, especially during myocardial ischemia or reperfusion (27). Because ß-adrenergic blockers have important antiarrhythmic properties and may reduce apoptic myocardial cell death (28), a combination of both substances in this situation may be useful. In our elderly patients, markers of myocardial ischemia (troponin T, CK-MB) in the postbypass period were significantly less increased in esmolol+enoximone-treated patients than in the untreated control group. This myocardial protective effect may be attributed to the use of the ß-adrenergic blocker, but the PDE III inhibitor may have also contributed to this effect because an increase in (myocardial) blood flow has been shown with this agent (6–9).

The beneficial effects of ß-adrenergic blocking substances is primarily related to HR reduction. Aside from this cardioprotective effect of ß-adrenergic blockers, this class of compounds may produce additional cellular effects by inhibition of protein kinases. By this mechanism, ß-adrenergic blockers affect endothelin synthesis, neutrophil chemotaxis, inflammation, nitric oxide synthesis, and other functions (29,30). In a retrospective database analysis covering approximately 2500 patients undergoing coronary artery bypass graft surgery, perioperative use of ß-adrenergic antagonists was associated with a substantial reduction in the incidence of postoperative neurological complications (31). These results indicated a potential neuroprotective effect of ß-adrenergic blockers in cardiac surgery patients aside from their myocardial properties.

Not only the heart and macrocirculation have profited from the prophylactic use of esmolol+enoximone in our study. Kidney and liver function were also preserved from the negative influence of CPB. This beneficial effect on organ function may mainly be attributed to the effects of PDE III inhibitors on (micro-) perfusion. Despite similar loading conditions (similar PCWP and central venous pressure) {alpha}- and ß-receptor agonists were needed in several of our control patients to improve myocardial performance and to guarantee perfusion pressure in the postbypass period. Catecholamines, however, may have negative effects on organ perfusion. PDE III inhibitors increase CO through combined positive inotropic and vasodilative effects ("inodilators"). Because altered microperfusion is an important mechanism for deteriorated organ function in the postbypass period, maintenance of adequate blood flow by the PDE III inhibitor may be an important maneuver.

The microvasculature is a key battleground for inflammatory processes, and there is evidence of a central role for the endothelium in modulating inflammation. The endothelium is not only an inert cellular layer; endothelial cells actively and reactively participate in inflammation and hemostasis (32). Both leukocytes and endothelial cells express particular adhesion molecules that are responsible for the cell-cell interactions. Trafficking and migration of leukocytes across the vascular endothelial barrier into tissues is modulated by this cell-cell interplay. The release of soluble adhesion molecules into the circulation correlated with the degree of trauma depending on the associated ischemia/reperfusion injury (33). An increased expression of adhesion molecule L-selectin (of more than double of baseline values) was seen after CPB (34). In an experimental study using human umbilical vein endothelial cells, the expression of ICAM-1 increased by 300% ± 41% in the presence of lipopolysaccharide and hypoxic conditions (35). It is widely accepted that CPB is associated with the risk of large increase in lipopolysaccharide plasma levels and tissue hypoxia (26). Plasma levels of all measured circulating adhesion molecules were significantly lower in our treated than in the control patients, indicating less endothelial injury in the esmolol+enoximone group. This may have been attributed either to the reduced inflammatory response as proinflammatory cytokines induced expression and release of adhesion molecules (36) or to improved (micro-) circulation that attenuated development of tissue hypoxia (35).

Organ protection should start as early as possible preoperatively and should be continued during the entire perioperative period (26). Thus, we started administration of esmolol+enoximone immediately after induction of anesthesia, more than one hour before the start of CPB. Because the decrease in CO by ß-adrenergic blockers may limit their use in patients with reduced myocardial function, we selected esmolol as the ß-adrenoceptor antagonist because of its short half-life that facilitates control of ß-blocking effects.

The beneficial, organ-protective effects of the combination of ß-adrenergic blockers and PDE III inhibitors in our elderly cardiac surgery patients have been confirmed in noncardiac surgery patients: long-term use of the ß-adrenergic blockers carvedilol and metoprolol in patients with chronic heart failure inhibited the favorable hemodynamic effects of dobutamine, whereas administration of the PDE III inhibitor enoximone resulted in improved hemodynamics in these patients (10,11).

No beneficial effects on outcome of the prophylactic use of the combination of esmolol and enoximone have been shown in our elderly patients. The study population was too small to detect significant differences in outcome (mortality), and outcome was not the major focus of this study. The beneficial effects on postbypass morbidity (e.g., organ function, endothelial integrity, inflammatory response), however, revealed some promising effects of this combination.

We conclude that the combination of the IV ß-adrenergic blocker esmolol and the PDE III inhibitor enoximone showed organ-protective properties (myocardium, kidneys, liver) in elderly patients undergoing cardiac surgery using CPB. Inflammatory response was attenuated and endothelial integrity and organ function were improved by administration of the combination of esmolol and enoximone. Large prospective randomized trials will be required to determine whether this approach improves outcomes.


   Footnotes
 
This study was not supported by a pharmaceutical company.


   References
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 

  1. London MJ. Perioperative beta blockade: facts and controversies. Ann Cardiac Anaesth 2003; 6: 117–25.
  2. Urban MK, Markowitz SM, Gordon MA, et al. Postoperative prophylactic administration of beta-adrenergic blockers in patients at risk for myocardial ischemia. Anesth Analg 2000; 90: 1257–61.[Abstract/Free Full Text]
  3. Coetzee A, Coetzee G. Beta-adrenergic blockade during severe ischemia. J Cardiothorac Vasc Anesth 2002; 16: 670–8.[Medline]
  4. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology 1998; 88: 7–17.[Web of Science][Medline]
  5. Vroom MB. Pharmacologic management of acute heart failure: a review. Sem Cardiothorac Vasc Anesth 1998; 2: 191–203.
  6. Lobato EB, Janelle GM, Urdaneta F, Martin TD. Comparison of milrinone versus nitroglycerin, alone and in combination, on grafted internal mammary artery flow after cardiopulmonary bypass: effects of alpha-adrenergic stimulation. J Cardiothorac Vasc Anesth 2001; 15: 723–7.[Web of Science][Medline]
  7. Levy JH, Bailey JM. Phosphodiesterase inhibitors: the inotropes of choice for the new millennium? J Cardiothorac Vasc Anesth 2000; 14: 365–6.[Medline]
  8. Ichioka S, Nakatsuka T, Sato Y, et al. Amrinone, a selective phosphodiesterase III inhibitor, improves microcirculation and flap survival: a comparative study with prostaglandin E1. J Surg Res 1998; 75: 42–8.[Web of Science][Medline]
  9. Carceles MD, Alexandre F, Fuente T, et al. Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. Eur J Anaesthesiol 2003; 20: 205–11.[Medline]
  10. Galie N, Branzi A, Magnani G, et al. Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile. Cardiovasc Drugs Ther 1993; 7: 337–47.[Web of Science][Medline]
  11. Metra M, Nodari S, D’Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40: 1248–58.[Abstract/Free Full Text]
  12. Knepper MA, Wade JB, Terris J, et al. Renal aquaporins. Kidney Int 1996; 49: 1712–7.[Web of Science][Medline]
  13. Weber MH, Verwiebe R, Janning G, et al. Applications of urinary indicator proteins in the non-invasive diagnosis of glomerular-tubular lesions of patients with chronic glomerulopathies and rheumatoid arthritis. Klin Wschr 1989; 67 (Suppl XVII): 48–51.
  14. Beckett GJ, Hayes JD. Glutathione S-transferases: biomedical applications. Adv Clin Chem 1993; 30: 281–380.[Web of Science][Medline]
  15. Boldt J, Brosch C, Piper SN, et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med 2001; 29: 952–8.[Web of Science][Medline]
  16. MacDonald P, Johnstone D, Rockwood K. Coronary artery bypass surgery for elderly patients: is our practice based on evidence or faith? CMAJ 2000; 162: 1005–6.[Free Full Text]
  17. Cook TM, Day CJ. Hospital mortality after urgent and emergency laparotomy in patients aged 65 years and over: risk and prediction of risk using multiple logistic regression analysis. Br J Anaesth 1998; 80: 776–81.[Abstract/Free Full Text]
  18. Rady MY. Perioperative determinants of morbidity and mortality in elderly patients undergoing cardiac surgery. Crit Care Med 1998; 26: 225–35.[Web of Science][Medline]
  19. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997; 112: 676–92.[Abstract/Free Full Text]
  20. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 1997; 63: 277–84.[Abstract/Free Full Text]
  21. Berendes E, Mollhoff T, van Aken H, et al. Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth Analg 1997; 84: 950–7.[Abstract]
  22. Frumento RJ, Bennett-Guerrero E. Systemic inflammatory response syndrome and organ dysfunction: opportunities for treatment. In: Newman MF, ed. Perioperative organ protection. A Society of Cardiovascular Anesthesiologists Monograph. Baltimore: Lippincott Williams & Wilkins, 2003: 1–27.
  23. Németh ZH, Haskó G, Szabó C, Vizi ES. Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice. Shock 1997; 7: 371–5.[Web of Science][Medline]
  24. Weiss M, Schneider EM, Liebert S, et al. Vasoactive drugs inhibit oxygen radical production of neutrophils. Immunopharmacol Immunotoxicol 1997; 19: 239–63.[Medline]
  25. Kern H, Schroder T, Kaulfuss M, et al. Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. Crit Care Med 2001; 29: 1519–25.[Web of Science][Medline]
  26. Mollhoff T, Loick HM, van Aken H, et al. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 1999; 90: 72–80.[Web of Science][Medline]
  27. Carceles MD, Aleixandre F, Fuente T, et al. Combined phosphodiesterase inhibition and beta-blockade in the GI104313 decreases ischemia-induced arrhythmias in the rat. Can J Anaesth 2001; 48: 486–92.[Web of Science][Medline]
  28. Zaugg M, Schaub MC, Pasch T, Spahn DR. Modulation of beta-adrenergic receptor subtype in perioperative medicine: mechanisms and sites of action. Br J Anaesth 2002; 88: 101–23.[Abstract/Free Full Text]
  29. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000; 36: 276–81.[Abstract/Free Full Text]
  30. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 2001; 33: 887–905.[Web of Science][Medline]
  31. Amory DW, Grigore A, Amory JK, et al. Neuroprotection is associated with beta-adrenergic receptor antagonists during cardiac surgery: evidence from 2,575 patients. J Cardiothorac Vasc Anesth 2002; 16: 270–7.[Web of Science][Medline]
  32. Galley HF. Cytokine-endothelial cell interaction. Br J Intensive Care 1999; 9: 147–51.
  33. Seekamp A, Jochum M, Ziegler M, et al. Cytokines and adhesion molecules in elective and accidental trauma-related ischemia/reperfusion. J Trauma 1998; 44: 874–82.[Web of Science][Medline]
  34. Toft P, Christiansen K, Tönnesen E, et al. Changes in adhesion molecule expression and oxidative burst activity of granulocytes and monocytes during open-heart surgery with cardiopulmonary bypass compared with abdominal surgery. Eur J Anaesthesiol 1998; 31: 283–8.
  35. Zünd G, Dzus AL, Pretre R, et al. Endothelial cell injury in cardiac surgery: salicylate may be protective by reducing expression of endothelial adhesion molecules. Eur J Cardiothorac Surg 1998; 13: 293–7.
  36. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993; 11: 767–84.[Web of Science][Medline]
Accepted for publication May 5, 2004.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
J. G. Stone, H. J. Khambatta, J. W. Sear, and P. Foex
Beta-Blockers: Must We Throw the Baby Out with the Bath Water?
Anesth. Analg., June 1, 2009; 108(6): 1987 - 1990.
[Full Text] [PDF]

Home page
 Br J AnaesthHome page
S. Suttner, J. Boldt, A. Mengistu, K. Lang, and J. Mayer
Influence of continuous perioperative beta-blockade in combination with phosphodiesterase inhibition on haemodynamics and myocardial ischaemia in high-risk vascular surgery patients
Br. J. Anaesth., May 1, 2009; 102(5): 597 - 607.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
S. J. Laing, A. R. Jackson, R. Walters, E. Lloyd-Jones, M. Whitham, N. Maassen, and N. P. Walsh
Human blood neutrophil responses to prolonged exercise with and without a thermal clamp
J Appl Physiol, January 1, 2008; 104(1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
K. E. A. Burns, M. W. A. Chu, R. J. Novick, S. A. Fox, K. Gallo, C. M. Martin, L. W. Stitt, A. P. Heidenheim, M. L. Myers, and L. Moist
Perioperative N-acetylcysteine to Prevent Renal Dysfunction in High-Risk Patients Undergoing CABG Surgery: A Randomized Controlled Trial
JAMA, July 20, 2005; 294(3): 342 - 350.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boldt, J.
Right arrow Articles by Isgro, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boldt, J.
Right arrow Articles by Isgro, F.
Related Collections
Right arrow Surgery
Right arrow Heart
Right arrow Pharmacology

Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2004 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press